Takeda Pharmaceutical Files 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: Jul 10, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Jul 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, regulatory-filing
TL;DR
Takeda filed a 6-K on 7/10/24, standard foreign issuer update.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on July 10, 2024, reporting information as a foreign private issuer. The filing indicates Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Takeda's status as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new material financial information or strategic changes.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Filer
- 0001395064-24-000135 (accession_number) — Filing identifier
- July 10, 2024 (date) — Filing date
- Tokyo, Japan (location) — Principal executive offices
FAQ
What type of filing is this Form 6-K?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
When was this Form 6-K filed?
This Form 6-K was filed on July 10, 2024.
Where are Takeda Pharmaceutical Company Limited's principal executive offices located?
Takeda Pharmaceutical Company Limited's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, 103-8668 Japan.
Does Takeda file its annual reports under Form 20-F or Form 40-F?
Takeda indicates it files its annual reports under Form 20-F.
What is the SEC file number for Takeda Pharmaceutical Company Limited?
The SEC file number for Takeda Pharmaceutical Company Limited is 001-38757.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 15 · Accepted 2024-07-10 06:04:02
Filing Documents
- form6k_071024.htm (6-K) — 11KB
- a2024-cg_report.htm (EX-99.1) — 121KB
- a2024-cg_report001.jpg (GRAPHIC) — 230KB
- a2024-cg_report002.jpg (GRAPHIC) — 277KB
- a2024-cg_report003.jpg (GRAPHIC) — 278KB
- a2024-cg_report004.jpg (GRAPHIC) — 280KB
- a2024-cg_report005.jpg (GRAPHIC) — 295KB
- a2024-cg_report006.jpg (GRAPHIC) — 281KB
- a2024-cg_report007.jpg (GRAPHIC) — 208KB
- a2024-cg_report008.jpg (GRAPHIC) — 211KB
- a2024-cg_report009.jpg (GRAPHIC) — 210KB
- a2024-cg_report010.jpg (GRAPHIC) — 212KB
- a2024-cg_report011.jpg (GRAPHIC) — 208KB
- a2024-cg_report012.jpg (GRAPHIC) — 213KB
- a2024-cg_report013.jpg (GRAPHIC) — 244KB
- a2024-cg_report014.jpg (GRAPHIC) — 261KB
- a2024-cg_report015.jpg (GRAPHIC) — 275KB
- a2024-cg_report016.jpg (GRAPHIC) — 251KB
- a2024-cg_report017.jpg (GRAPHIC) — 249KB
- a2024-cg_report018.jpg (GRAPHIC) — 252KB
- a2024-cg_report019.jpg (GRAPHIC) — 266KB
- a2024-cg_report020.jpg (GRAPHIC) — 292KB
- a2024-cg_report021.jpg (GRAPHIC) — 253KB
- a2024-cg_report022.jpg (GRAPHIC) — 46KB
- a2024-cg_report023.jpg (GRAPHIC) — 81KB
- a2024-cg_report024.jpg (GRAPHIC) — 177KB
- a2024-cg_report025.jpg (GRAPHIC) — 216KB
- a2024-cg_report026.jpg (GRAPHIC) — 166KB
- a2024-cg_report027.jpg (GRAPHIC) — 197KB
- 0001395064-24-000135.txt ( ) — 8578KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date July 10, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller